Incidence, risk factors, and outcome of BK polyomavirus infection after kidney transplantation

Table 1 Donor, transplant, and recipient characteristics of the study population

Variables	Median (IQR) or n (%)
Patients	629
Recipient Male : Female	372:257
Caucasian ethnicity	279/629 (44.3)
Afro-Caribbean ethnicity	114/629 (18.1)
Recipient age (yr)	47 (36-55)
Recipient body mass index (kg/m²)	25.2 (22.2-27.5)
Pre-transplant diabetes	83/629 (13.2)
Pre-transplant cardiovascular disease	62/629 (9.9)
Recipient cytomegalovirus IgG positive	431/629 (68.5)
Glomerular disease	185/629 (29.4)
Polycystic kidney disease	71/629 (11.3)
Tubular-interstitial nephropathy	81/629 (12.9)
Diabetic nephropathy	49/629 (7.8)
Hypertension	55/629 (8.7)
Unknown renal disease	141/629 (22.4)
Other renal disease	47/629 (7.5)
Haemodialysis	295/629 (46.9)
Peritoneal dialysis	136/629 (21.6)
Peritoneal dialysis and haemodialysis	118/629 (18.8)
Pre-emptive transplant	80/629 (12.7)
Panel-reactive antibody > 50%	101/629 (16.1)
Primary transplant	550/629 (87.4)
Deceased donor	395/629 (62.8)
Donation after brain death donor	263/629 (41.8)
ABO-incompatible transplant	25/629 (4.0)
Donor age (yr)	48 (39-57)
Donor-recipient gender mismatch	340/629 (54.1)
Donor cytomegalovirus IgG positive	354/629 (56.3)
Cytomegalovirus D+R- immunization	83/629 (13.2)
Cold ischemia time (hours)	12 (4-16)
Cold ischemia time >12 h	282/629 (44.8)
Cumulative HLA mismatch	3 (2-4)
HLA mismatch > 4	92/629 (14.6)
Induction treatment
Anti-IL2-receptor antagonist	431/629 (68.5)
Rabbit anti-thymocyte globulin	169/629 (26.9)
Rituximab	25/629 (4.0)
Alemtuzumab	3/629 (0.5)
Muromonab-CD3	1/629 (0.2)
Maintenance immunosuppression
CyA-MMF-steroid	422/629 (67.1)
CyA-AZA-steroid	3/629 (0.5)
Tacrolimus-MMF-steroid	109/629 (17.3)
Tacrolimus-AZA-steroid	79/629 (12.6)
Tacrolimus-MMF	12/629 (1.9)
Tacrolimus-AZA	2/629 (0.3)
AZA-MMF-steroid	1/629 (0.2)
AZA-steroid	1/629 (0.2)
CyA-based scheme	425/629 (67.6)
Tacrolimus-based scheme	202/629 (32.1)
CNI-free scheme	2/629 (0.3)
MMF-containing scheme	544/629 (86.5)
AZA-containing scheme	86/629 (13.7)
Steroid-free scheme	14/629 (2.2)
Cytomegalovirus prophylaxis	241/629 (38.3)

IQR: Interquartile range; IgG: Immunoglobulin class G; HLA: Human leukocyte antigen; CyA: Cyclosporine; MMF: Mycophenolate mofetil; AZA: Azathioprine; CNI: Calcineurin inhibitor.